Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia

NCT00017342 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00017342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2001
Completion date
June 30, 2005
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia